Omega-3 solutions for the 
pharmaceutical industry

Omega-3 Pharma Solutions


Leading the omega-3 pharma market

We work daily with the reference standard for prescription omega-3-acid ethyl esters

BASF had a long success story with the introduction of Omacor®/Lovaza™ to the pharmaceutical market. We also offer omega-3-acid ethyl esters in 1g capsules, simplifying your supply chain.

Omega 3’s are shown to improve:

  • Hypertriglyceridemia
  • Post-myocardial infarction

We offer omega-3-acid ethyl esters (K85EE) as an encapsulated formulation.


Benefit from our strengths:

  • Simplified product supply chain

  • World leading expertise, experience and support for analysis, regulatory control, production and supply

  • Guaranteed continuous supply from FDA approved production sites

  • Long-term strategic commitment to the business

Omega-3-acid ethyl esters capsules 1g

Omega-3-acid ethyl esters capsules 1g contain a minimum 43% EPA and 34% DHA and minimum 90% of total omega-3-acid ethyl esters.

Chemically Eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester, the Omega-3-acid ethyl esters capsules 1g comply with the US pharmacopoeia (USP) and is documented in a US-DMF.

Research & Development

20 years of experience in pharma

Value-Chain Management

Trusted collaboration with our partners

Regulatory Affairs

Dedicated to omega-3

Our Solutions